Ligand Pharmaceuticals

Quarterly Financials

Values in thousands2025-09-302025-06-302025-03-312024-12-31
Revenue
$115,461
$47,627
$45,333
$42,812
Gross Profit
90,641
44,720
40,484
39,975
EBITDA
149,232
20,898
-40,543
-29,690
EBIT
141,137
12,376
-49,313
-38,317
Net Income
117,273
4,847
-42,451
-31,088
Net Change In Cash
115,461
47,627
45,333
42,812
Free Cash Flow
13,146
15,583
-25,730
27,759
Cash
139,376
67,669
47,989
72,307
Basic Shares
20,170
19,926
19,191
18,974

Annual Financials

Values in thousands2024-12-312023-12-312022-12-312021-12-31
Revenue
$167,133
$131,314
$196,245
$241,544
Gross Profit
156,059
96,265
143,418
179,368
EBITDA
40,794
100,837
81,204
142,770
EBIT
5,555
64,316
37,810
91,824
Net Income
-4,032
52,154
-33,361
57,138
Net Change In Cash
167,133
131,314
196,245
241,544
Cost of Revenue
-28,440
Free Cash Flow
77,407
-4,272
119,927
70,037
Cash
72,307
22,954
45,006
19,522
Basic Shares
18,290
17,757
16,868
17,246

Earnings Calls

QuarterEPS
2025-12-31
$0
2025-09-30
$3.09
2025-06-30
$1.60
2025-03-31
$1.33